MERCAPTOPURINE

Post-LOE

Viatris

ANDAORALTABLET

Approved

Jul 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MERCAPTOPURINE by Viatris is (tgns). First approved in 2005.

Drug data last refreshed 3h ago

$0.0BPart D

Mechanism of Action

(TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (3)

NCT01324336N/ACompleted

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

Started Jul 2011

40 enrolled

Acute Lymphoblastic Leukemia

NCT00774982Phase 1Completed

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Started Dec 2008

12 enrolled

Crohns Disease

NCT00648336Phase 1Completed

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

Started Nov 2003

60 enrolled

Healthy

Company

Worked on MERCAPTOPURINE at Viatris? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.